TY - JOUR T1 - Measurement of hypoxia in the lung in idiopathic pulmonary fibrosis: a matter of control JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.02711-2021 SP - 2102711 AU - Pierre-Simon Bellaye AU - Guillaume Beltramo AU - Olivier Burgy AU - Bertrand Collin AU - Alexandre Cochet AU - Philippe Bonniaud Y1 - 2021/01/01 UR - http://erj.ersjournals.com/content/early/2021/11/18/13993003.02711-2021.abstract N2 - We have read with great interest the paper by JC Porter and colleagues published in the October 2021 issue of the European Respiratory Journal [1]. The authors’ aim was to explore the potential benefit of the hypoxia tracer [18F]fluoromisonidazole ([18F]F-MISO) in idiopathic pulmonary fibrosis (IPF). Given the lack of non-invasive imaging tools for the diagnosis and/or the follow-up of patients with IPF, this study appears to be an essential first step towards the personalised management of IPF patients through imaging biomarkers for early/active fibrosis. In vivo molecular imaging, in particular positron emission tomography (PET), has become a crucial tool in preclinical research, clinical trials and medical practice, especially in the field of oncology. In lung fibrosis, recent advances have been made with the aim of developing molecular imaging tools in preclinical models, a necessary step toward clinical certification [2]. Among tracers validated at the preclinical level, imaging probes targeting collagen (68Ga-CBP8 [3]), integrins ([18F]FB-A20FMDV2, [4]) and glucose metabolism ([18F]FDG, [5]) have been successfully evaluated in clinical trials and may ultimately improve IPF management.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Pierre-Simon Bellaye reports a research grant paid to his institution (Centre George François Leclerc, Dijon) from the ANR (HYMAGE-IPF – ANR-20-CE17-0005).Conflict of interest: Guillaume Beltramo reports a research grant paid to his institution (CHU Dijon) from GIRCI Est (FIPOXY).Conflict of interest: Olivier Burgy has nothing to disclose.Conflict of interest: Bertrand Collin has nothing to disclose.Conflict of interest: Alexandre Cochet has nothing to disclose.Conflict of interest: Philippe Bonniaud reports receiving support for attending medical and research conferences and personal fees for their role in the advisory board of Roche and Boehringer. ER -